key: cord-0841471-zgodda84
authors: Gaspar-Marques, João; van Zeller, Mafalda; Carreiro-Martins, Pedro; Loureiro, Cláudia Chaves
title: Severe asthma in the era of COVID-19: a narrative review
date: 2021-04-30
journal: Pulmonology
DOI: 10.1016/j.pulmoe.2021.04.001
sha: 38cc475227b3f30768b833af2e8f72f061fcad32
doc_id: 841471
cord_uid: zgodda84

Introduction and objectives: Severe asthma management during the coronavirus disease 2019 (COVID-19) pandemic is a challenge and will continue to be, at least in the next few months, as herd immunity is still a mirage. A lot has to be learned about how COVID-19 affects underlying diseases, and severe asthma is no exception. Methods: Narrative review of papers available until February 2021 in PubMed and Google Scholar, relating severe asthma and COVID-19. Four main research topics were reviewed: SARS-CoV-2 infection: immunology and respiratory pathology; interrelationship of severe asthma endotypes and COVID-19 disease mechanisms; severe asthma epidemiology and COVID-19; and biologics for severe asthma in the context of COVID-19. Results: COVID-19 disease mechanisms start with upper respiratory cell infection, and afterwards several immunological facets are activated, contributing to disease severity, namely cell-mediated immunity and antibody production. Although infrequent in the COVID-19 course some patients develop a cytokine storm that causes organ damage and may lead to acute respiratory distress syndrome or multiorgan failure. Regarding severe asthma endotypes, type2-high might have a protective role both in infection risk and disease course. There is conflicting data regarding the epidemiological relationship between COVID-19 among severe asthma patients, with some studies reporting increased risk of infection and disease course, whereas others the other way round. Biologics for severe asthma do not seem to increase the risk of infection and severe COVID-19, although further evidence is needed. Conclusions: Globally, in the era of COVID-19, major respiratory societies recommend continuing the biologic treatment, preferably in a self-home administration program.

During the coronavirus disease 2019 (COVID- 19) pandemic, severe asthma management is a challenge and will continue to be at least in the following months.

Despite the recent approval and use of COVID-19 vaccines, the milestone of herd immunity is yet away from reality worldwide 1 . COVID-19 is caused due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has caused a substantial increase in hospitalizations for pneumonia with multiorgan disease 2 .

COVID-19 first emerged in December 2019 2 and, by the end of 2020, has affected almost every country in the globe, resulting in more than 79 million cases and more than 1.9 million deaths 3 . It is not clear why the clinical presentation may be so distinct, ranging from mild and even asymptomatic to severe clinical conditions such as pneumonia, acute respiratory distress syndrome (ARDS), organ dysfunction and death 4 .

Endemic human coronaviruses present a high homology with SARS-CoV-2 5 . Crossreactivity exists between these coronaviruses and may explain less severe COVID-19 as reported 6 . Early in infection, SARS-CoV-2 targets cells, such as nasal and bronchial epithelial cells and pneumocytes. Subsequently, the viral inflammatory response is generated, consisting of innate and adaptive immunity (comprising humoral and cellmediated immunity) 2, 7 . The pathogenesis of COVID-19 results from an abnormal host response or overreaction of the immune system in some patients with unknown etiology 7 . From a theoretical perspective, asthmatic patients should have increased susceptibility for SARS-CoV-2 infection and to severe COVID-19 due to a deficient antiviral immune response and the tendency for exacerbation elicited by common respiratory viruses 8 . At the beginning of the pandemia, the inclusion of asthmatic patients and patients with other chronic lung diseases in a high-risk population for SARS-CoV-2 infection was based more on common sense than on scientific evidence 9 .

Available data at the moment has not shown consistently an expected increased burden of asthmatic individuals among COVID-19 patients 8 .

Severe asthma represents 3-10% of the nearly 400 million asthmatics worldwide but is associated with increased mortality and hospitalization, reduced quality of life and increased healthcare costs 10 . Authorities and physicians are still learning how COVID-19 affects underlying diseases, and severe asthma is not an exception. Even though respiratory viruses are among the most common triggers for asthma exacerbations, not all of these viruses affect patients equally. Available data about whether patients with asthma are at higher risk of being infected with SARS-CoV-2 or having severe forms of the disease is somewhat conflicting.

In the last months, several papers have been published about the relationship between asthma and COVID-19 but a recent review about the particularities and novelties of severe asthma is lacking. Taking into consideration the complexity of severe asthma pathophysiology and the growing knowledge about COVID-19, the authors aim to review four different research topics about the possible interactions between these disease entities:

 SARS-CoV-2 infection: immunology and respiratory pathology  Interrelationship of severe asthma endotypes and COVID-19 disease mechanisms  Severe asthma epidemiology and COVID-19

 Biologics for severe asthma in the context of COVID-19

The author team generated the topics mentioned above before initiating the review. To answer these questions, a search was performed on PubMed and Google Scholar for papers relating to severe asthma and COVID-19 until February 2020. The search strategy was structured to include terms for "severe asthma" AND "COVID-19" OR "SARS-CoV-2". Data was then narratively synthesized by the research topic. Due to the emerging nature of evidence in this field, a broad approach to inclusion was followed, without any study type restriction. All the references judged to have relevant information about prespecified questions were included.

Upon entry into the host, the inhaled SARS-CoV-2 is likely to bind to epithelial cells in the nasal cavity and start replicating 11 . Angiotensin-converting enzyme-2 (ACE2) is the primary receptor for both SARS-CoV-2 and SARS-CoV 11 . The cellular protease TMPRSS2 also appears vital for SARS-CoV-2 cell entry 12 . There is local propagation of the virus but a limited innate immune response 11 . At this stage, the virus can be detected by nasal swabs and although the viral burden may be low, these individuals are infectious 11 . The virus propagates and migrates down the respiratory tract along the conducting airways, and a more robust innate immune response is triggered 11 . For about 80% of the infected patients, the disease will be mild and mostly restricted to the upper and conducting airway 13 . This phase would be the result of the infection itself.

Unfortunately, about 20% of the infected patients will progress and develop pulmonary infiltrates and some of these might develop very severe disease 13 . The virus reaches the lung's gas exchange units and infects alveolar type II cells with high surface expression of ACE2 receptors. The virus rapidly disseminates through peripheral blood to other organs like the heart, kidney, liver, spleen, etc 14, 15 . The cytokine storm generated damages the organs or may lead to ARDS or multiorgan failure in COVID-19 [16] [17] [18] . Human SARS-CoV-2 infection involves the innate immune response, T and B cell immunity and antiviral neutralizing antibodies.

Interrelationship of severe asthma endotypes and COVID-19 disease mechanisms

The current severe asthma approach relies on disease phenotypes identification, but these do not necessarily relate to or give insights into the underlying pathogenetic mechanisms described by disease endotypes 19 . Based on the major immuneinflammatory pathway involved, type2-high, type2-low and mixed endotypes are described for severe asthma 19 .

Type-2 immune responses predominantly mediate the majority of the disease. The type-2 immune response involves T helper (Th) 2 cells, type-2 B cells, group 2 innate lymphoid cells, type-2 macrophages, IL-4-secreting nature killer and natural killer T cells, basophils, eosinophils, and mast cells 8 . A variety of cytokines produced by the immune system and epithelial cells contribute to the regulatory network 8 . For example, IL-4 and IL-13 have essential roles in allergen-specific IgE production and accumulation of Th2 cells and eosinophils in local tissues, as well as epithelial barrier regulation. At the same time, IL-5, IL-9, and IL-13 contribute to eosinophilia and mucus production 8 .

Allergic asthmatic subjects seem to be less likely to be infected by the SARS-CoV-2, which could be due to different factors 20 . The first hypothesis might be related to the anti-inflammatory effect of the inhaled corticosteroids (ICS) and their negative impact on the cytokine storm elicited by the virus 20 . This effect might be boosted by increased compliance with asthma treatment driven by COVID-19 fear 20 . Individuals with allergic asthma have confirmed reduced ACE2 expression 21 and in vitro experiments showed that IL-13 also reduced the ACE2 expression 21 . Interestingly, ICS were associated with lower expression of ACE2 and TMPRSS2 after adjustment for asthma severity and may explain the low prevalence of asthma among COVID-19 patients in some studies 22 . This fact may justify why data about the relationship between asthma and susceptibility to SARS-CoV-2 is contradictory, as compliance with ICS might be an Certain aspects of the type-2 immune response, including type 2 cytokines (IL-4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19 due to its anti-inflammatory effects 8, 23 . For example, IL-4 can suppress type-1 immune response 8 . This effect is obtained not only by suppression of Th1 cells development but also by the inhibition in the production of multiple proinflammatory cytokines associated with type-1 immune response, including IL-1β, TNFα, IL-6, and IL-12 8 . It has also been shown that IL-13 has immunoregulatory effects through inhibiting the secretion of pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, and TNF-α) and chemokines (IL-8, MIP-1α and MIP-1β, and monocyte chemotactic protein-3) 8 . Additionally, IL-13 mediated type-2 inflammation has a significant role in ACE2 downregulation and TMPRSS2 upregulation 7, 22 . Furthermore, IL-9 reduces TNF-α and IL-10, but increases the secretion of TGF-β on LPS-activated monocytes 8 . It is possible, that predominance of type 2 cytokines might counteract the accumulation of pro-inflammatory cytokines, including the pathogenesis of COVID-19 8 . Increased tissue migration is unlikely because eosinophils infiltration was not found in pulmonary tissue of COVID-19 patients, but further research is needed 21 . An important fact is that eosinophil levels improved in patients before discharge, suggesting that eosinophil resolution may be an indicator of improvement of clinical condition 24 .

Type2-low severe asthma is a distinct endotype with relevant features such as increased severity and remodelling and less satisfactory response to anti-inflammatory treatment 19 . The understanding of these disease mechanisms lags far behind type2high endotype 19 . Several pathways were evaluated, such as the dysregulated innate immune response, including intrinsic neutrophil abnormalities, the inflammasome pathway and the activation of the IL-17 pathway 19 . In severe asthma with predominantly neutrophilic phenotype, transcobalamin-1, metalloproteinase (MMP) 9, mucins, and oxidative stress responses are upregulated 19 . Many severe asthma facets are mechanistically associated with Th17 cell-derived cytokines and other immune factors that mediate neutrophilic influx to the airways and remodelling 19 . TGF-β1 is a pivotal mediator involved in airway remodelling that correlates with enhanced Th17 activity and is essential for Th17 differentiation and IL-17A production. IL-17A can reciprocally enhance activation of TGF-β1 signalling pathways, whereas combined Th1/Th17 or Th2/Th17 immune responses additively impact severity 19 . Type2-low and IFN-high individuals were found to express a high level of ACE2, and this might increase the risk of SARS-CoV-2 infection 22 , but further evidence is needed to corroborate this finding.

Neutrophils are one of the predominant lungs infiltrating leukocytes in severe COVID-19 and neutrophilia predicts poor clinical outcomes 21 . Post-mortem analysis of lung samples from COVID-19 patients showed neutrophil infiltration in pulmonary capillaries and neutrophil extravasation into the alveolar space, and the inflammatory profile observed in lungs from COVID-19 patients is Th1, Th17 phenotype 21, 24 . In experimental models of smoke-induced acute respiratory distress, a Th17/neutrophilic syndrome, ACE2 was upregulated 26 . A type 2-low endotype can be an aggravating factor to COVID-19 severity 27 .

Under neutrophil-activating conditions, such as those occurring during systemic inflammation, neutrophil extracellular traps (NETs) can be released 28 . Although this is a way to trap pathogens, NET formation is linked to pulmonary diseases, particularly ARDS 28 . Severe COVID-19 conditions with uncontrollable progressive inflammation presumably induce intense crosstalk between neutrophils releasing NETs and IL-1β secretion from macrophages 28 .

At the present moment, we could not find any information relating to mixed endotypes of severe asthma and COVID-19 and this is an area of particular research interest. the authors speculated about the role of these monoclonal antibodies (mAbs) in the COVID-19 course. It should be noted that this finding was not seen in the Belgian registry 29 . In the Italian cohort, the related mortality was 7.7%, lower than in the general Italian population (14.5%).

In the Italian Registry of Severe Asthma (IRSA) 31 , a different Italian severe asthma registry, seven subjects out of 558 (1.25%) contracted COVID-19. The hospitalization rate in COVID-19 infected patients with severe asthma was similar to the general population, and no deaths were reported. The proportion of COVID-19 in patients on biologics was 5.43% compared to 0% on subjects treated with ICS-LABA alone, but no statistical difference was found.

Eger et al. 32 Caminati et al. 34 The proportion of asthmatic patients using ICS plus long-acting beta2-agonists admitted to an intensive care unit was higher (57.9%) than those using ICS alone. Kow et al. 37 suggest that this finding may indicate that those with more severe disease have worse outcomes. According to the health analytics platform OpenSafely 38 that covers 40% of all patients in England, severe asthma (defined as asthma with recent use of an oral corticosteroid) was associated with COVID-19 related death after adjusting for sex and age (hazard ratio: 1.13; 95%: 1.01-1.26).

Calmes D. et al. 39 conducted a study to evaluate if obstructive diseases were risk factors for intensive care unit stay and death due to COVID-19. Twenty out of 57 (35%) asthmatic patients included were under a high dose of inhaled steroids, and 2 (3%) were taking oral steroids daily. In this study, inhaled and oral corticosteroid treatment were not identified as risk factors.

Biologics for severe asthma in the context of COVID-19

There are now five approved biologic agents for severe asthma: one anti-IgEomalizumab, two anti-IL5 -mepolizumab and reslizumab, one anti-IL5 receptor alpha (Rα)benralizumab -and the anti-IL-4Rα dupilumab 40 .

Omalizumab is a humanized monoclonal antibody that selectively binds to human IgE, preventing its high-affinity receptor 41 From another perspective, it is theoretically reasonable that mAbs targeting type-2 asthma inflammation can be associated with increased risk for COVID-19 (in terms of infection or severity). However, early reports did not show this clearly 42 . Available data did not show consistently significant differences among patients treated with different mAbs in a large cohort study 42 . Even though, contradictorily, in the Severe Asthma Network in Italy (SANI), patients treated with anti-IL5 mAbs had a considerably higher proportion of SARS-CoV-2 (71%) compared to those treated with anti-IgE (29%) 30 and this possible effect about increased disease severity in patients treated with biologics for type-2 inflammation has been further debated in another recent study 32 . Although the number of cases was too small to draw any definitive conclusions, the authors speculated that different mAbs could have specific and distinct impact on antiviral immune response, as suggested for anti-IgE as protective for other viral infections 30 .

Furthermore, the authors also proposed that the consequence of eosinopenia induced by anti-IL5 agents might be a risk factor for more severe COVID-19. Currently, no large series of severe asthmatics treated with biologicals infected by COVID-19 have been published, so the ideas about the role of mAbs in modulating the risk of COVID-19 are speculations and need further evidence 30 . Assuming the previously stated notion that eosinopenia associated with COVID-19 is likely to be a secondary phenomenon, this concern about biological drug-induced eosinopenia may not be relevant 25 .

Comprehensive and large-scale investigations are expected to elucidate further the interactions between COVID-19 and type-2 high severe asthma. Treatment with omalizumab might protect from severe forms of COVID-19 43 .

Omalizumab was shown to enhance antiviral immunity via downregulation of the highaffinity IgE receptor on plasmacytoid dendritic cells, essential for antiviral immune responses 43 . Cases of omalizumab patients who contracted COVID-19 have been recorded, and no increased susceptibility to severe disease or asthma exacerbations was observed 43, 44 . The PROSE study showed that in severe asthmatics, omalizumab treatment decreases the duration of viral infections, viral shedding and the risk of respiratory viral illnesses 45 . Another study indicated that omalizumab treatment augments plasmacytoid dendritic cells IFN-α responses and attenuates the FcεRIα protein expression induced by these cells, reducing the susceptibility to virus-induced asthma exacerbations 46 . Besides, IL-33 levels decrease after omalizumab treatment 47, 48 and this interleukin is important for the production of pro-inflammatory cytokines (including IL-6, IL-1β, TNF-α, MCP-1, and prostaglandin D2) 49 . All this data suggests a potential effect of omalizumab on antiviral responses 8 . It would be interesting to explore whether previous or concurrent use of omalizumab might have protective effects on COVID-19 infection, either on duration, severity or both 8 .

In those on mepolizumab therapy, a very recent publication reports the outcomes of four severe asthmatic patients with COVID-19 while receiving treatment with mepolizumab, from different centres (UK, Italy and North America) 50 . Only one patient (who had recognized risk factors for admission and death from COVID-19) required hospitalization and ventilatory support but recovered without evidence of long-term respiratory consequences 50 . Four published case reports describe six patients contracting SARS-CoV-2 while receiving benralizumab treatment for severe eosinophilic asthma. The range of symptoms experienced by each patient varied, but all of them recovered 51-53 . These reports add to the debate about whether patients with eosinophil targeting therapies might have an unaltered outcome in COVID-19. As previously mentioned, evidence of severe asthma registries still poses this into question 32 . Considering the reported evidence, it is clear that more data is needed.

Until then, and for the moment, in severe eosinophilic asthma the expert recommendations are to continue biologic therapy unchanged 54 .

Case reports of severe asthma patients under dupilumab show no association with negative impact in COVID-19 55, 56 . However, as previously mentioned, dupilumab will block IL-4, which is fundamental for the differentiation of Th2 by IL-6 and this might shift the balance Th1/Th2 towards Th1 and facilitate INFγ production 57 . The differentiation of Th2 by IL-6 is dependent on endogenous production of IL-4 whose activity is significantly reduced by dupilumab 57 . This mechanism plays a central role in the "cytokine storm" damaging lung in COVID-19 patients 57 but the clinical consequences are still a matter of debate 32, 56 . On the other hand, due to the mechanism of action of dupilumab, drug discontinuation could be associated with higher susceptibility toward infections, even if there is no evidence supporting this hypothesis regarding SARS-CoV-2 57 . Considering available evidence at the moment, treatment with dupilumab should not be stopped during the COVID-19 pandemic.

Globally, in the era of COVID-19, major respiratory societies (Global Initiative for Asthma, European Respiratory Society, British Thoracic Society and American Academy of Allergy, Asthma & Immunology) recommend continuing the biologic treatment, preferably in a self-administered home program.

Evidence about COVID-19 is rapidly evolving, and data connecting asthma and COVID-19 is also trendy. A recent systematic review and meta-analysis about asthma and COVID-19 suggested that the prevalence of asthma among COVID-19 patients is similar to the global prevalence of asthma58. Another interesting conclusion from this study is that people with asthma have a lower risk than those without asthma for acquiring COVID-19 and have similar clinical outcomes 58 . Despite the increasing number of published studies about COVID-19 and asthma, the knowledge gap for severe asthma persists due to its particularities. The relationship between COVID-19 and severe asthma is nowadays still a matter for debate as conflicting evidence is published. In the following months with the burden of COVID-19 increasing in terms of mortality and healthcare resources utilization, severe asthma patients will face a hard Interestingly, as time goes by, several aspects apart from the disease itself start to be shown about the impact of COVID-19 pandemic on severe asthma patients. A recent study concluded that during this period, severe asthma patients were significantly more impacted by the pandemic with increased rates of unemployment and difficulty in getting asthma meds compared to those with non-severe asthma 62 .

Recent publications have discussed the concept of a long-COVID syndrome that is common and independent from the severity of the acute COVID-19 syndrome 63 . This syndrome is more frequent in women and may not be directly attributable to the effect of SARS-CoV-2 but rather an interaction of biopsychosocial effects 63  What are the possible interactions between mAbs directed for COVID-19 treatment and mAbs for severe asthma treatment?

Severe asthma management during the COVID-19 pandemic is now a challenge that will continue in the near future until herd immunity is reached.

COVID-19 disease mechanisms affect severe asthma patients and definitely, the disease endotypes might confer different responses. The immunological consequences of SARS-CoV-2 infection are broad and complex, contributing to the increasing complexity of severe asthma knowledge. Regarding severe asthma endotypes, type2-high seems to have a protective role both in SARS-CoV-2 infection and COVID-19 course. On the other hand, type-2 low seems to confer an increased risk of infection and severe disease forms. From a theoretical point of view, although this idea might be defensible further robust evidence is needed to corroborate it. Biologics for severe asthma do not seem to increase the risk of infection and severe COVID-19 and might even be protective, although further evidence is needed. Globally, in the era of COVID-19, major respiratory societies recommend continuing the biologic treatment, preferably in a self-administrated home program. 

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Coronavirus disease (COVID-19) Epidemiological

COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Recent endemic coronavirus infection is associated with less-severe COVID-19

The Immune Response and Immunopathology of COVID-19

COVID-19 and Asthma: Reflection During the Pandemic

Severe asthma and COVID-19: lessons from the first wave

EAACI Biologicals Guidelines-Recommendations for severe asthma

Pathogenesis of COVID-19 from a cell biology perspective

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Severe asthma phenotypes and endotypes

Severe asthma at COVID-19 time: what's new on biologic therapies

Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy

Hughes-Visentin A, Paul ABM. Asthma and COVID-19: What do we know now

Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19

Eosinophil responses during COVID-19 infections and coronavirus vaccination. The Journal of allergy and clinical immunology

Receptor in Asthma and Coronavirus (SARS-CoV2

Inhaled Corticosteroids and COVID-19

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry

COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry

Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy. Respiratory medicine

Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak. The journal of allergy and clinical immunology In practice

Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respiratory medicine

Severe asthma during the COVID-19 pandemic: Clinical observations. The journal of allergy and clinical immunology In practice

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? Allergy

Factors associated with COVID-19-related death using OpenSAFELY

Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection. The journal of allergy and clinical immunology In practice

Biologics for the Treatments of Allergic Conditions: Severe Asthma. Immunol Allergy Clin North Am

Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak. The journal of allergy and clinical immunology In practice

Early experiences of SARS-CoV-2 infection in severe asthmatics receiving biologic therapy. The journal of allergy and clinical immunology In practice

Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma

Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. The Journal of allergy and clinical immunology

Interleukin-25, Vitamin-D and Interleukin-33 Levels in Patients with Allergic Asthma

Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy

33 induces the release of pro-inflammatory mediators by mast cells. Cytokine

COVID-19 in a severe eosinophilic asthmatic receiving benralizumab -a case study

COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth

COVID-19, severe asthma, and biologics

Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Arzteverband Deutscher Allergologen (AeDA)(A)

Luxemburgische Gesellschaft fur Allergologie und

Osterreichische Gesellschaft fur Pneumologie (OGP)(F) in co-operation with the German, Austrian, and Swiss ARIA groups(G), and the European Academy of Allergy and Clinical Immunology (EAACI)(H)

Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology

Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia

Dupilumab and COVID-19: What should we expect? Dermatol Ther

Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis

How a torrent of COVID science changed research publishingin seven charts

Waste in covid-19 research

Asthma and COVID-19: do we finally have answers?

Asthma care during COVID-19: differences in attitudes and expectations between physicians and patients

What is Long-COVID and How Should We Manage It? Lung

Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology

This paper would not have been possible without the tremendous effort of all healthcare professionals that produced scientific evidence at the same time as managing COVID-19 in the wards and emergency rooms all over the World. To all of them our sincere gratitude.

No funding to declare.